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Abstract. 
 
The characterization of distinct subnuclear 
domains suggests a dynamic nuclear framework sup-
porting gene expression and DNA replication. Here, 
we show that the glutamic acid/arginine-rich domain 
protein YT521-B localizes to a novel subnuclear struc-
ture, the YT bodies. YT bodies are dynamic compart-
ments, which ﬁrst appear at the beginning of S-phase in 
the cell cycle and disperse during mitosis. Furthermore, 
in untreated cells of the human cell line MCF7 they 
were undetectable and appeared only after drug-
induced differentiation. YT bodies contain transcrip-
tionally active sites and are in close contact to other 
subnuclear structures such as speckles and coiled bod-
ies. YT bodies disperse upon actinomycin D treatment, 
whereas other transcriptional inhibitors such as
 
a
 
-amanitin or DRB have little effect. On the basis of 
our experiments, we propose that YT521-B may partici-
pate in the assembly of genes into transcription centers, 
thereby allowing efﬁcient regulation of gene expres-
sion.
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Introduction
 
The compartmentalization of the nucleus into discrete do-
mains contributes to the complexity of processes involved
in gene expression and its regulation. Various detection
methods have revealed an increasing number of distinct
subnuclear structures, and the characterization of the pro-
teins contained within these domains opens up the possi-
bility to investigate their function. The best characterized
compartment to date, the nucleolus, is the site of rRNA
synthesis and pre-ribosomal assembly, whereas the func-
tions of most other subnuclear structures are much less
clear (reviewed in Matera, 1999; Spector, 1993; Nickerson
et al., 1995).
Several classes of subnuclear domains have been ob-
served. Some, such as the nucleolus and coiled bodies, ful-
fill particular roles in the maturation of processing RNAs,
for example snRNPs or rRNA, and were therefore called
nuclear factories (Matera, 1999). Other nuclear factories,
such as the Oct1/PTF/transcription (OPT)
 
1
 
 domain, con-
stitute a compartment where a specific group of genes is
brought together, thereby making transcriptional regula-
tion more efficient (Pombo et al., 1998). Recently, it was
shown that at least a subset of promyelocytic leukemia
(PML) bodies and the perinuclear compartment (PNC)
rapidly accumulate FITC-labeled nucleotides, suggesting
 
that they may be sites of transcriptional activity (Huang
et al., 1998; LaMorte et al., 1998). However, it cannot be
excluded that the transcripts were initially synthesized
elsewhere and then translocated into these compartments.
Another domain class is formed by the human polycomb
group complex (PcG), which localizes to specific hetero-
chromatic regions, suggesting a role in the constitutive re-
pression of transcription (Saurin et al., 1998).
 
Some nuclear domains are storage compartments, where
certain proteins are kept in an inactive or inaccessible
form. Regulatory mechanisms, such as phosphorylation,
control the release of these proteins into the nucleoplasm,
where they assemble into functional units. Prominent mem-
bers of this class are the speckles, which are considered to
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be storage compartments for splicing factors (Spector,
1993; Misteli and Spector, 1998). Moreover, some tran-
scription factors have been shown to localize in discrete
dots throughout the nucleus, and it is thought that these
may also represent storage compartments since they do
not coincide with regions of transcriptional activity (van
Steensel et al., 1995). Nuclear factories and storage com-
partments are dynamically linked to RNA polymerase ac-
tivity. Speckles change their morphology under the influ-
ence of transcriptional inhibitors (Spector et al., 1983;
Carmo-Fonseca et al., 1992; Misteli et al., 1997; Nayler et al.,
1998b) and coiled bodies change their composition upon
transcriptional inhibition and eventually disperse (Carmo-
Fonseca et al., 1992; Matera, 1999). Recently, it was shown
that transcription and replication sites, which are both ac-
tive during S-phase, are found in distinct and separate sub-
nuclear domains, and it was proposed that overlapping
sites are temporally separated. This implicates that a given
site is either transcriptionally active or replicates (Wei et al.,
1998). Together with the characterization of novel subnu-
clear domains, these results provide further evidence for
the existence of a dynamically regulated nuclear architec-
ture supporting the compartmentalization of the nucleus
(Nakayasu and Berezney, 1989; Jackson et al., 1993; Ma et al.,
1998).
We previously identified a nuclear protein, YT521-B, as
a 110-kD protein containing an amino-terminally located
glutamic acid–rich domain (E-box) and a characteristic
glutamic acid/arginine–rich domain (ER-domain) at the
carboxy-terminal end (Hartmann et al., 1999). ER-domain
proteins comprise a growing number of molecules and sev-
eral family members are involved in RNA metabolism
(Hartmann et al., 1999). Moreover, it was suggested that
ER repeat proteins may contribute to the development of
neurodegenerative diseases (Assier et al., 1999). Tran-
siently expressed EGFP-YT521-B fusion proteins local-
ized to the nucleus and displayed a characteristic pattern
of nuclear bodies, which varied in number and size. Fur-
thermore, transient expression of YT521-B modulated
splicing of reporter minigenes in a dose dependent man-
ner. Using immunoprecipitation and yeast two-hybrid ex-
periments, we have shown that YT521-B interacts with
scaffold attachment factor B (SAF-B) and the 68-kD Src
substrate associated during mitosis (Sam68; Hartmann et al.,
1999). SAF-B forms a ternary complex with RNA poly-
merase II and SR proteins at the so-called scaffold or ma-
trix attachment regions (SAR/MAR; Nayler et al., 1998a).
Sam68, an RNA binding protein, colocalizes with YT521-
B in nuclear dots, which dispersed upon coexpression of
the Src family kinase p59
 
Fyn
 
 (Hartmann et al., 1999). To-
gether, these results suggested that p59
 
Fyn
 
-induced signal
transduction pathways could affect RNA metabolism
through SAF-B, Sam68, and YT521-B.
Here, we have investigated the localization of the en-
dogenous YT521-B protein and show that it defines a
novel subnuclear domain, termed YT bodies. YT bodies
were found in a proportion of cells in a variety of cell lines,
although they were undetectable in the human cell line
MCF7. There, YT bodies only formed after sodium bu-
tyrate-, PMA-, or tamoxifen-induced cell differentiation.
In vivo, actinomycin D, but no other transcriptional inhib-
itor, reversibly perturbed the localization of YT521-B into
 
discrete domains. Our results suggest that the YT521-B
protein displays novel biochemical characteristics and may
participate in the organization of chromosomal domains
independently of RNA polymerase activity.
 
Materials and Methods
 
Antisera
 
A rabbit polyclonal antiserum (PK2) was raised against a mixture of two
YT521-B protein peptides (P1: RSARSVILIFSVRESGKFQCG; P2:
KDGELNVLDDILTEVPEQDDECG) fused to keyhole-limpet hemo-
cyanin. Anti-EGFP antibodies were from Boehringer. Anti–SAF-B anti-
bodies have been described previously (Nayler et al., 1998a). Anti-SC35
antibodies were from Sigma-Aldrich. Anti-PML antibody mAb5E10 was
donated by R. van Driel (Stuurman et al., 1992). The anti–p80-coilin anti-
body 5P10-pi (Almeida et al., 1998) was donated by Maria Carmo-Fon-
seca and the 66 cd4 antibody against gems (Liu et al., 1997) by U. Fischer.
Secondary CY3-coupled antibodies were from Dianova.
 
Cell Culture
 
HEK293, COS7 cells, and BHK cells were maintained in DME supple-
mented with 10% (vol/vol) FCS (Sigma-Aldrich). MCF7 cells were main-
tained in RPMI 1640 supplemented with 10% (vol/vol) FCS. For immuno-
labeling experiments, cells were grown on glass coverslips in 6-cm cell
culture dishes.
Actinomycin D (Sigma-Aldrich) was added at 0.04 
 
m
 
g/ml for 3 h to in-
hibit RNA polymerase I, or at 50 
 
m
 
g/ml to inhibit RNA polymerase I, II,
and III (Huang et al., 1998; Perry, 1963). 5,6-dichloro-1-
 
b
 
-ribofuranosyl-
benzimidazole (DRB) was added at 75 
 
m
 
M for 3 h to inhibit RNA poly-
merase II (Sehgal et al., 1976). 
 
a
 
-Amanitin (Sigma-Aldrich) was added at
50 
 
m
 
g/ml for 5 h to inhibit RNA polymerase II or at 300 
 
m
 
g/ml to inhibit
RNA polymerase II and III (Pombo et al., 1999). Cycloheximide (Sigma-
Aldrich) was added at 100 
 
m
 
g/ml for 5 h to inhibit protein synthesis and
RNA polymerase I activity (Higashi et al., 1968). Inhibition of actinomy-
cin D was reversed by changing the medium twice, followed by 2 h of
drug-free incubation.
 
Cell Cycle Analysis
 
BHK cells were grown to 60–80% confluence and blocked at the G2/M
phase with 0.5 
 
m
 
g/ml nocodazole for 4 h. Mitotic cells were then removed
by tapping on the cell culture dish, washed, and seeded on glass coverslips
(Spector et al., 1998a). The cells were incubated for 2, 4, 6, and 8 h before
fixation. Staining was performed as described above, using anti–YT521-B
antiserum (PK2). At each time point, 500,000 cells were trypsinized,
stained with propidium iodide, and analyzed by flow cytometry as de-
scribed (Spector et al., 1998a).
 
MCF7 Differentiation
 
1 
 
3
 
 10
 
6
 
 MCF7 cells were seeded in 10-cm cell culture dishes containing
4 glass coverslips and grown for 24 h. Cells were then incubated with 1
 
m
 
M sodium butyrate (Calbiochem-Novabiochem), 1 
 
m
 
g/ml Phorbol 12-
myristate 13-acetate (PMA; Biomol), or 5 
 
m
 
M Tamoxifen (Calbiochem-
Novabiochem) for a further 48 h. The glass coverslips were removed and
the cells fixed in 3.7% formaldehyde and PBS for 10 min at room temper-
ature. The cells remaining in the cell culture dish were lysed in 600 
 
m
 
l
RIPA and benzonase as described above and 10 
 
m
 
l lysate supernatant was
analyzed in Western blot experiments using the anti–YT521-B antiserum
(PK2). Two glass coverslips were used for immunostaining with anti–
YT521-B antiserum (PK2). The remaining two glass coverslips were used
to determine the number of cells containing lipid droplet inclusions. They
were first stained with 1% oil red O and 60% triethylphosphate (Sigma-
Aldrich) for 15 min, washed in PBS, followed by 100% Haemalaun stain-
ing (Merck) for 15 min, and washed in PBS (Novikoff et al., 1980).
 
Immunolabeling
 
1
 
 3 
 
10
 
5
 
 BHK cells were grown on glass coverslips in 3.5-cm culture dishes
for 24 h before fixation and immunostaining. Alternatively, they were
transfected 24 h after seeding as described and incubated for further 24 h.
Cells were fixed in 3.7% formaldehyde and PBS for 10 min at room tem- 
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perature, washed three times in PBS and 0.1% Triton X-100, and blocked
in PBS, 0.1% Triton X-100, and 3% bovine serum albumine (Sigma-Aldrich)
for 30–60 min at room temperature. Cells were then incubated with the
appropriate antibody (diluted in PBS, 0.1% Triton X-100, and 3% bovine
serum albumin) overnight at 4
 
8
 
C and washed three times in PBS and 0.1%
Triton X-100. Cells were then incubated with CY3-coupled secondary an-
tibody (Dianova) in PBS and 0.1% Triton X-100 for 2 h at room tempera-
ture, washed three times in PBS and 0.1% Triton X-100, and mounted on
glass slides in Fluormount (Dianova). The cells were examined either by
laser scanning fluorescent microscopy (Leica; Figs. 1 D, 2, 3 B, 4, and 5) or
by conventional microscopy (ZEISS), followed by deconvolution using
the Openlab software (Improvision; Fig. 3 A and 6).
 
Nucleotide Incorporation Assay
 
The nucleotide incorporation assay was performed using BHK cells as de-
scribed (Spector et al., 1998b). Cell permeabilization was with 0.02% digi-
tonin for 2 min, incubation time for RNA elongation was 20 min at 30
 
8
 
C.
Br-UTP incorporation was detected with a monoclonal anti-BrdU anti-
body (Boehringer) and YT bodies were detected using PK2. Incubation
on ice with primary and secondary antibodies was for 1 h each. Control in-
cubations were performed in transcription cocktails containing actinomy-
cin D (50 
 
m
 
g/ml). Quantitative analysis was performed using the Optimas
program. The Br-UTP signal was defined as region of interest and the
amount of YT521-B and Br-UTP overlap was calculated using the double
standard deviation of the Br-UTP signal as threshold.
 
Transfections
 
3
 
 3 
 
10
 
5
 
 HEK293 cells were seeded per 3.5-cm dish and were transiently
transfected with 0.5–1 
 
m
 
g plasmid DNA using the calcium precipitation
method as described previously (Stoss et al., 1999). In single plasmid
transfections, 0.5 
 
m
 
g of expression plasmid was used, and in cotransfec-
tions 0.5 
 
m
 
g of each plasmid was used. Cells were harvested 24 h after
transfection. 3
 
 3 
 
10
 
5
 
 COS7 or BHK cells were seeded per 3.5-cm dish and
transfected with a total of 1.5 
 
m
 
g plasmid DNA (0.5 
 
m
 
g of construct and 1 
 
m
 
g
of empty carrier vector) and 10 
 
m
 
l Superfect (QIAGEN), according to the
manufacturer’s instructions. The expression constructs pEGFP-YT521-B
(Hartmann et al., 1999) and pFlagSCA1[82] (Skinner et al., 1997) were
used.
 
Cell Lysis and Western Blotting
 
6
 
 3 
 
10
 
5
 
 cells were lysed for 30 min on ice in 200 
 
m
 
l buffer containing 50 mM
Hepes, pH 7.5, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1 mM
EDTA, 20 mM sodium pyrophosphate, 2 mM sodium orthovanadate,
100 mM NaF, 5 mM 
 
b
 
-glycerophosphate, 1 mM PMSF, and 1 
 
m
 
g/ml apro-
tinin (HNTG buffer). The lysates were centrifuged at 13,000 
 
g
 
 for 15 min
at 4
 
8
 
C, 200 
 
m
 
l 2
 
3
 
 SDS sample buffer was added to the supernatant, and
400 
 
m
 
l 2
 
3
 
 SDS sample buffer was added to the remaining pellet. The
probes were mixed, boiled for 5 min, and 15 
 
m
 
l of each fraction loaded
onto 10% SDS–polyacrylamide gels (Nayler et al., 1997). Alternatively,
cells were lysed for 30 min on ice in 200 
 
m
 
l RIPA buffer (0.01 M sodium
phosphate, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl,
2 mM EDTA, 1 mM NaF, 4 mM sodium orthovanadate, 5 mM 
 
b
 
-glycerol-
phosphate, 1 mM PMSF, 1 
 
m
 
g/ml aprotinin, and 100 U/ml benzonase;
Nayler et al., 1998b). Lysates were centrifuged for 15 min at 4
 
8
 
C, 200 
 
m
 
l
2
 
3
 
 SDS sample buffer was added to the supernatant, and 400 
 
m
 
l 2
 
3
 
 SDS
sample buffer was added to the pellet. 15 
 
m
 
l of the fractions was loaded in
each lane and analyzed on 10% SDS–polyacrylamide gels. The SDS–poly-
acrylamide gel–separated proteins were blotted on nitrocellulose mem-
branes (Schleicher & Schuell) using a semi-dry blotting device. The ECL
system was used for immunoblot detection (Amersham Pharmacia Bio-
tech).
 
Nuclear Extraction
 
COS7 cells were transfected with 0.5 
 
m
 
g pEGFP-YT521-B as described
and incubated for 24 h. Nuclear extraction experiments were essentially
performed as described (Patturajan et al., 1998). In brief, cells were per-
meabilized in TBS buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, and
5 mM MgCl
 
2
 
) containing 0.5% Triton X-100 and 0.5 mM PMSF. Cells
were then incubated in TBS alone, in TBS containing 20 U/ml benzonase
(Sigma-Aldrich), or in TBS containing 4 U/ml DNase-free RNase (Sigma-
Aldrich). Finally, cells were extracted with TBS and 0.2 M ammonium
sulfate, fixed in 3.7% formaldehyde and PBS for 5 min, and incubated
with 1 
 
m
 
g/ml Hoechst no. 33258 and PBS.
 
Results
 
The PK2 Antiserum Is Specific for YT521-B
 
We have previously shown that a transiently expressed
EGFP fusion protein of the novel nuclear protein YT521-B
concentrates in distinct nuclear foci that vary in size and
number. We suggested that these dots may represent nu-
clear storage compartments from which the protein is
released into the nucleoplasm (Hartmann et al., 1999).
Similar models were recently proposed for other nuclear
proteins such as SR proteins (Misteli and Spector, 1998),
SAF-B (Nayler et al., 1998a), or RED (Assier et al., 1999).
To address the subcellular localization of the endogenous
YT521-B protein, we generated polyclonal sera raised
against YT521-B peptides and tested their specificity. In
Western blot experiments from HEK293 cell lysates con-
taining transiently expressed EGFP or EGFP-YT521-B
fusion protein, one of our antisera, PK2, detected a pro-
tein corresponding to the EGFP-YT521-B protein (Fig. 1,
A and B). Moreover, in EGFP-YT521-B and EGFP-con-
taining cell lysates, we detected an additional band of
 
z
 
110 kD that corresponded in molecular mass to the en-
dogenous YT521-B protein (Fig. 1 A). The signal intensi-
ties of both EGFP-YT521-B and endogenous 110-kD pro-
tein were significantly reduced when the antigenic peptide
was added to the antibody solution, suggesting that the
PK2 antiserum specifically recognized the YT521-B pro-
tein in Western blot experiments (Fig. 1 A). Similarly, we
detected endogenous YT521-B in protein lysates of COS7
(Fig. 1 C), BHK (data not shown), and MCF7 cell lines
(see below).
To investigate the subcellular localization of the protein
recognized by the PK2 antiserum, we performed immuno-
labeling experiments in COS7 and BHK cells. In both cell
lines we detected a punctuated nuclear staining in a pro-
portion of cells (Fig. 1 D). This pattern corresponded with
the previously observed localization of EGFP- and FLAG-
tagged YT521-B proteins (Hartmann et al., 1999). Again,
the pattern was not visible when the antigenic peptide was
added to the antibody solution (data not shown). We have
noticed, that the endogenous staining pattern was less pro-
nounced than the one observed with EGFP-YT521-B fu-
sion protein and that the observed dots displayed fuzzy
boundaries. Upon higher magnification, the boundaries of
overexpressed EGFP-YT521-B appeared to be quiet fuzzy,
too (data not shown). Together, these experiments suggest
that our PK2 antiserum specifically detects endogenous
YT521-B in Western blot and immunolabeling experi-
ments. Moreover, the subnuclear localization of the en-
dogenous YT521-B protein in discrete subnuclear do-
mains is similar to overexpressed fusion protein.
 
YT-containing Dots Are Regulated during the Cell 
Cycle and Appear after Tamoxifen, Sodium Butyrate, 
and PMA Treatment of the Human Mammary 
Adenocarcinoma Cell Line MCF7
 
We noticed a variability in the number of YT bodies
among cells, suggesting that an intrinsic cellular property 
The Journal of Cell Biology, Volume 150, 2000 952
 
influences the formation of these structures. To investigate
this further, we used BHK cells and endogenous YT521-B
protein to test whether the formation of YT bodies is regu-
lated during the cell cycle. The cells were blocked at the
G2/M phase and then released to allow progression
through G1 and S phase (Fig. 2 A). Staining at different
time points illustrates that YT bodies started to form when
cells entered the S-phase. In most cells, both number and
distinct definition of YT bodies increased at later stages of
S-phase (6 and 8 h; Fig. 2 B). These experiments demon-
strate that endogenous YT bodies are regulated during the
cell cycle and that their appearance correlates with the on-
set of transcriptional activity.
To explore this further, we employed the human cell
line MCF7. This is a a mammary adenocarcinoma cell line
that can be differentiated using sodium butyrate, PMA, or
tamoxifen (Maas et al., 1995). After a 48-h incubation pe-
riod in the presence of these drugs, MCF7 cells arrest in
G1 and accumulate cytoplasmic lipid droplets, which are
visualized using oil red O staining. After drug treatment,
the number of MCF7 cells displaying lipid droplets clearly
increased (Fig. 3 A). Less than 10% of all MCF7 cells con-
tained lipid droplets in the absence of drugs, whereas
 
.
 
90% of the cells did in sodium butyrate-treated cells. 40–
60% of the cells contained lipid droplets after PMA treat-
ment and 
 
.
 
70% of the cells after tamoxifen treatment.
In immunofluorescence studies, we detected a diffuse
nuclear staining of endogenous YT521-B in untreated MCF7
cells, and no YT bodies were observed (Fig. 3 B). However,
after treatment with sodium butyrate, PMA, or tamoxifen,
a dramatic change in the localization of the endogenous
YT521-B protein was observed. YT bodies were now very
obvious in a majority of cells, suggesting that the differen-
tiation process had also induced changes in the subnuclear
structure. To rule out a change in the amount of YT521-B,
we performed Western blot analysis and loaded equal
amounts of RIPA lysate per lane. We detected no signifi-
cant change in the amount of YT521-B protein in the pres-
ence or absence of drug treatment (Fig. 3 C).
 
YT521-B Localizes to a Novel
Subnuclear Compartment
 
Endogenous YT521-B and the transiently expressed EGFP-
YT521-B fusion protein are concentrated in distinct nuclear
bodies. Several nuclear proteins were shown to reside in
subnuclear domains such as the nucleolus, the perinuclear
compartment, coiled bodies, speckles, or PML bodies (re-
viewed in Matera, 1999). Here, we wished to determine
whether the YT521-B containing dots coincide with any of
those known structures displaying a similar morphology or
behavior. To address the identity of the YT521-B contain-
Figure 1. Specificity of the anti–
YT521-B antiserum. (A) Total
RIPA/benzonase cell lysates of
HEK293 cells expressing EGFP
or EGFP-YT521-B were loaded
onto 10% SDS-PAGE gels and
analyzed by Western blot using
the anti–YT521-B antiserum
PK2 in the absence (2peptide)
or presence (1peptide) of the
antigenic YT521-B peptide. (B)
Reblot of (A) using an anti-
EGFP antibody. (C) Total COS7
RIPA and benzonase cell lysate
(CL) was analyzed by SDS-
PAGE and Western blot using
anti–YT521-B antiserum PK2.
The YT521-B proteins detected
are indicated by arrows. Molecu-
lar mass standards are given in
kD. (D) BHK (left) and COS7
cells (right) were fixed in 3.7%
formaldehyde and immuno-
stained with the anti–YT521-B
antiserum PK2 using a second-
ary CY3-coupled antibody for
detection. 
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ing dots, we compared the localization of reported marker
proteins with endogenous YT521-B protein in immunola-
beling experiments.
Previously, we demonstrated that transiently expressed
YT521-B modulates alternative splicing of reporter mini-
genes in a concentration-dependent manner, suggesting that
it interacts with components of the splicing machinery
(Hartmann et al., 1999). To this end, we first tested the
splicing factor SC35 that is now widely used as a marker
protein for nuclear speckles (Fu and Maniatis, 1992). Co-
staining of endogenous SC35 and YT521-B revealed a dif-
ferent staining pattern of both markers (Fig. 4 A). How-
ever, we found that SC35 and YT521-B protein localize in
foci that were in close proximity (Fig. 4 A, boxed). A
higher magnification (Fig. 4 B) revealed that in these areas
YT521-B containing structures did not overlap, but were
rather surrounding speckles, suggesting a molecular cross-
talk of both compartments. Similar results have been ob-
tained with overexpressed EGFP-YT521-B (Hartmann et al.,
1999, and data not shown).
Similarly, we could not detect a colocalization of
YT521-B containing dots with PML bodies (Fig. 4 C),
p80-coilin-containing structures (Fig. 4 D) or nuclear
gems (Fig. 4 E). However, p80-coilin–containing dots
were often found in direct contact with YT521-B contain-
ing dots. Furthermore, no colocalization of either hnRNP
L or RED protein with YT521-B was observed (data not
shown).
The nuclear polyglutamine-containing protein SCA-1 is
localized in nuclear inclusions that become much more fre-
quent when the polyglutamine stretch is expanded (Skinner
et al., 1997). Nuclear inclusions, which are formed by SCA-1
and other proteins containing expanded polyglutamine re-
peats, can cause neurodegenerative diseases (Hardy and
Gwinn-Hardy, 1998). Strikingly, the size and number of
the SCA-1(SCA-1[85]) inclusion bodies resembled the
structures observed with EGFP-YT521-B fusion proteins
(Hartmann et al., 1999; Skinner et al., 1997). Therefore, we
investigated whether transiently expressed SCA-1[82]-Flag
colocalizes with EGFP-YT521-B. As shown in Fig. 4 F,
EGFP-YT521-B–containing dots did not coincide with
SCA-1[82]-Flag protein structures, suggesting that, unlike
other nuclear proteins, YT521-B is not drawn into aggre-
gates formed by the SCA-1[82] protein.
In summary, we found that the YT521-B–containing
dots do not coincide with any other known subnuclear
structures, suggesting that the YT521-B protein forms a
novel compartment, which we named YT bodies.
Figure 2. YT521-B structures are regulated during the cell cycle. BHK cells were arrested at the G2/M phase using nocodazole and then
incubated in absence of the drug for 2, 4, 6, and 8 h (as indicated). Cells were then fixed and used for FACS analysis or stained with
anti–YT521 antiserum (PK2). A. FACS analysis of the cells. An open arrow indicates the G1, a closed arrow the G2/M population of
cells. (B) Images of representative cells at the various time points. 
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YT Bodies Contain Focal Sites of Transcription
 
Accumulating evidence supports the idea that the nucleus
is organized into higher-order structures comprising segre-
gated domains of transcriptional and replicational activity
(Wei et al., 1998). However, this may not be restricted to
the organization of the genome into chromosomal do-
mains alone, but may extend to an underlying organization
of the supporting nuclear architecture, which could be in-
volved in the regulation of gene activity (Stein et al., 1998).
Based on these findings, we investigated whether YT bod-
ies colocalize with sites of RNA synthesis using in situ
BrUTP incorporation (Jackson et al., 1993; Huang et al.,
1998). BHK cells were permeabilized and incubated in an
RNA synthesis buffer in the presence of BrUTP. After fix-
Figure 3. YT521-B structures are markers for the drug-induced differentiation of the cell line
MCF7. MCF7 cells were incubated in the presence of sodium butyrate, PMA, tamoxifen, or with-
out drugs for 48 h. (A) The degree of differentiation was assessed by phase contrast microscopy af-
ter fixation in 2% formaldehyde with oil red O staining. The lipid droplet inclusions are shown
with an arrow. (B) After drug treatment, MCF7 cells were fixed in 3.7% formaldehyde, and immu-
nostaining was performed using the anti–YT521-B antiserum, followed by CY3-coupled secondary
antibodies. The cells are shown at two different magnifications as indicated. Arrows indicate the
formation of distinct YT bodies. The cytoplasmatic staining observed in differentiated cells is in-
dependent of the YT521-B antiserum and represents most likely an unspecific binding of the sec-
ondary antibody to lipid containing components. (C) A portion of the MCF7 cells were lysed in
RIPA and benzonase after drug treatment and equal amounts (20 mg) of the soluble fraction were
loaded on 10% SDS-PAGE, followed by Western blot analysis using the anti–YT521-B antiserum
PK2. The detected endogenous YT521-B protein is indicated by an arrow; the molecular mass
markers are given in kD. 
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Figure 4. YT521-B protein lo-
calizes to a novel subnuclear
compartment. BHK cells were
fixed with 3.7% formaldehyde
and immunostained with anti-
bodies against nuclear markers
(left) and YT521-B (middle).
The following proteins were
used: (A and B) SC35, B is an
enlargement of the area indi-
cated with a box in A; (C) PML;
(D) p80-coilin; (E) SMN. In
(F),  cells were cotransfected
with pFlagSCA1[82] (red) and
pEGFP-YT521-B (green). In
A–E, YT521-B was detected us-
ing a CY3-coupled secondary
antibody (red) and the other nu-
clear component was visualized
with a FITC labeled secondary
antibody (green). 
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ation, the BrUTP epitope was labeled with a specific mono-
clonal antibody. As shown in Fig. 5 A, YT bodies contain
multiple sites of BrUTP incorporation. The area containing
YT bodies harbors an increased amount of BrUTP incor-
poration activity when compared with the surrounding nu-
cleoplasma. A statistical analysis shows that 37.5 (
 
6
 
3.5%)
of BrUTP containing dots are present in YT bodies. To
investigate the specificity of the labeling we performed
BrUTP incorporation experiments in presence of the tran-
scriptional inhibitor actinomycin D and detected no
BrUTP incorporation (Fig. 5 B). Furthermore, actinomy-
cin D treatment also dissolved YT bodies. These experi-
ments show that YT bodies coincide with focal sites of
transcription and suggest that the formation of YT bodies
may depend on the activity of RNA polymerases.
 
YT Bodies Are Sensitive to Actinomycin D Treatment
 
YT bodies contain focal sites of transcription and are
formed during S-phase of the cell cycle. This suggests that
YT bodies are dynamic structures that could be involved
in gene expression. Therefore, we studied the dynamic be-
havior of YT bodies under the influence of known tran-
scriptional or translational inhibitors more closely. We
used COS7 cells transiently expressing EGFP-YT521-B
and, after drug treatment, cells were analyzed and quanti-
fied by fluorescence microscopy.
 
Initially, cells were treated for 5 h with 50 
 
m
 
g/ml 
 
a
 
-ama-
nitin, which blocks transcription through its direct inhibition
of RNA polymerase II (Weinman et al., 1974). As seen in
Fig. 6, 
 
a
 
-amanitin had no visible effect on the subnuclear
domains defined by EGFP-YT521-B, and caused only a
modest reduction in the percentage of cells displaying YT
bodies (41% in untreated and 31% in 
 
a
 
-amanitin–treated
cells). Similarly, DRB, which blocks transcription through
inhibition of an upstream kinase of RNA polymerase II
(Sehgal et al., 1976; Zandomeni and Weinmann, 1984),
had little effect on the quality or quantity of the YT bodies
(32% in DRB-treated cells). A very different picture was
observed after a 3-h treatment with actinomycin D at a
concentration of 50 
 
m
 
g/ml (high ActD). Actinomycin D
binds to GC-rich double stranded DNA, permitting RNA
initiation, but blocking RNA elongation (Perry, 1963). At
a concentration of 50 
 
m
 
g/ml, actinomycin D inhibits all
three RNA polymerases, and we observed a complete loss
of YT bodies. However, the dispersed dots reappeared
after a 2-h incubation period after removing the in-
hibitor (high ActD 
 
1
 
 resc.), suggesting that the effect is
fully reversible. The same effect of actinomycin D was ob-
served when endogenous YT521-B was analyzed (data not
shown). At a lower actinomycin D (low ActD) concentra-
tion (0.04 
 
m
 
g/ml actinomycin D) or after cycloheximide
(100 
 
m
 
g/ml) treatment (Cyclo), only RNA polymerase I is
blocked (Perry, 1963; Higashi et al., 1968) and no changes
Figure 5. YT bodies contain focal sites of transcription. (A and B) BHK cells were permeabilized with digitonin. After a 20-min incuba-
tion period at 308C in transcription buffer in the absence of transcription inhibitors (A), or 50 mg/ml actinomycin D (B), cells were fixed.
BrUTP incorporation was detected using anti-BrdU antibodies and CY3-coupled secondary antibodies. YT521-B was detected with
PK2 antiserum. The localization of YT521-B (red) and sites of BrUTP incorporation (green) are shown. Colocalization is visible in the
overlay (orange). Some specific sites of colocalization are highlighted with an arrow. The data are the averages of three independent ex-
periments and 150 cells were analyzed in each. 
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Figure 6. Actinomycin D revers-
ibly dissolves YT bodies. COS7 cells
were transiently transfected with
pEGFP-YT521-B and treated with
50 mg/ml  a-amanitin for 5 h (a-
amanitin), 0.04 mg/ml actinomycin D
for 3 h (low ActD), 75 mM DRB for
3 h (DRB), 50 mg/ml actinomycin D
for 3 h (high ActD), 100 mg/ml cy-
cloheximide for 5 h (Cyclo), or they
were treated with 50 mg/ml actino-
mycin D, followed by a 2-h incuba-
tion period in the absence of the
drug (high ActD 1 resc.). The per-
centage of cells containing YT521-B
domains was determined by count-
ing individual cells in three indepen-
dent experiments. The data are the
averages of three independent ex-
periments (6SD) and 150 cells were
counted in each. 
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in the number of cells containing YT bodies were ob-
served (45% in low actinomycin D–treated cells and 40%
in cycloheximide-treated cells). Additionally, to eliminate
the possibility that the observed effect was due to RNA
polymerase III inhibition, we incubated the cells with 300
 
m
 
g/ml 
 
a
 
-amanitin (Weinman et al., 1974) and detected no
significant effects (data not shown).
 
YT Bodies Are Dynamic, Triton
X-100–soluble Structures
 
Several recently described subnuclear domains are associ-
ated with an insoluble, proteinaceous scaffold, the nuclear
matrix. It was proposed that some of those structures may
constitute storage compartments from which proteins are
released into the nucleoplasma, whereas others represent
functional units for gene expression (reviewed in Lamond
and Earnshaw, 1998; Spector, 1993; Nickerson et al., 1995;
Huang, 2000). It was also shown that the phosphorylation
of proteins regulates their release or uptake into nuclear
compartments and that transcriptional activity can influ-
ence the balance of compartmentalized versus noncom-
partmentalized proteins (Colwill et al., 1996; Lyon et al.,
1997; Huang et al., 1998; Misteli and Spector, 1998; Nayler
et al., 1998b; Hartmann et al., 1999). YT bodies dispersed
after actinomycin D treatment, but there was little effect
after incubation with other transcriptional inhibitors (see
above). On the basis of our previously established pro-
tocol to separate nuclear proteins into a soluble nucleo-
plasmic and insoluble fraction (Nayler et al., 1998b), we
investigated the solubility of transiently expressed EGFP-
YT521-B protein in the presence or absence of actinomy-
cin D, and compared it with the solubility of a previously
characterized nuclear matrix associated protein SAF-B
(Renz and Fackelmayer, 1996; Oesterreich et al., 1997;
Nayler et al., 1998a; Weighardt et al., 1999). The EGFP-
YT521-B protein was detected in the pellet (P) frac-
tion and in the soluble (S) fraction of a 1% Triton X-100–
based cell lysis buffer (HNTG) in absence of actinomycin
D (Fig. 7 A). However, upon actinomycin D treatment,
the amount of HNTG soluble protein was significantly re-
duced and the amount of protein in the corresponding pel-
let fraction increased (Fig. 7 A). In contrast, when we used
a RIPA/benzonase lysis buffer, which releases most nu-
clear proteins, we detected almost all endogenous YT521-
B protein in the soluble fraction and there was no change
observed after actinomycin D treatment. The HNTG solu-
bility of the endogenous nuclear matrix-associated protein
SAF-B was not affected by actinomycin D (Fig. 7 B), un-
 
and ECL using the anti–SAF-B antibody. (C) HEK293 cells were
transiently transfected with EGFP (control) or pEGFP-YT521-
B. The pEGFP-YT521-B transfected cells were then incubated
with 50 
 
m
 
g/ml actinomycin D for 3 h (ActD), 100 
 
m
 
g/ml cyclohex-
imide for 5 h (Cyclo), 50 mg/ml a-amanitin for 5 h (a-amanitin),
75 mM DRB for 3 h, or they were incubated with 50 mg/ml actino-
mycin D for 3 h, followed by a 2-h actinomycin D–free incubation
in the presence (ActD1wash/cyclo) or the absence (actD1wash)
of 100 mg/ml cycloheximide. Equal amounts of the soluble frac-
tions of HNTG cell lysates were analyzed on 10% SDS-PAGE
and Western blotting using the anti-EGFP antibody. (D)
HEK293 cells were transiently transfected with EGF (control) or
pEGFP-YT521-B. The pEGFP-YT521-B–transfected cells were
then incubated with increasing amounts of actinomycin D for 1
or 3 h. Equal amounts of the soluble fractions of HNTG cell ly-
sates were analyzed on 10% SDS-PAGE and Western blot using
the anti-EGFP antibody. The detected proteins are indicated by
arrows; the molecular mass is indicated in kD.
Figure 7. YT bodies are dynamic, Triton X-100–soluble compart-
ments. (A) HEK293 cells were transiently transfected with
pEGFP-YT521-B, incubated with 50 mg/ml actinomycin D for 3 h,
and lysed in RIPA and benzonase or HNTG. Equal amounts of
the soluble fraction (S) or redissolved pellet fraction (P) were
loaded onto 10% SDS-PAGE gels. Proteins were analyzed by
Western blot and ECL using the anti-EGFP antibody. (B) HEK
293 cells incubated with 50 mg/ml actinomycin D for 3 h and lysed
in RIPA and benzonase or HNTG. Equal amounts of the soluble
fraction (S) or redissolved pellet fraction (P) were loaded onto
10% SDS-PAGE gels. Proteins were analyzed by Western blotNayler et al. YT Bodies and Transcription 959
derlining the specificity of the actinomycin D effect for
YT521-B, as most of the SAF-B protein was only soluble
in RIPA/benzonase as previously described (Nayler et al.,
1998a). To investigate the solubility of the YT521-B pro-
tein further we incubated EGFP-YT521-B expressing cells
with actinomycin D, a-amanitin, DRB, or cycloheximide
and lysed them in HNTG (Fig. 7 C). Again, we see a re-
versible reduction of soluble YT521-B protein upon acti-
nomycin D treatment (ActD and ActD1wash), whereas
no effects were detected using the other transcription in-
hibitors a-amanitin and DRB, or the translation inhibitor
cycloheximide. Moreover, the reappearance of YT521-B
protein in the soluble fraction after removal of actinomy-
cin D was not dependent on de novo protein synthesis,
since cycloheximide did not suppress this effect during
the recovery phase (ActD1wash/cyclo). The removal of
YT521-B protein from the soluble fraction after actinomy-
cin D treatment was dose dependent and detectable at
concentrations of 50 mg/ml actinomycin D after only 1 h of
incubation. Lower concentrations of actinomycin D had
no visible effect in Western blot experiments, even after
3 h of treatment (Fig. 7 D).
Together, our biochemical and immunolocalization ex-
periments showed that the YT521-B protein resides in two
separable compartments, an HNTG soluble and an HNTG
insoluble nuclear fraction. In addition, these experiments
also suggested that there is a dynamic exchange between
these compartments and, most interestingly, that YT bod-
ies comprise the soluble fraction.
Discussion
Recently, we analyzed the novel nuclear YT521-B protein
(Hartmann et al., 1999) and observed the formation of nu-
clear bodies in a proportion of cells expressing EGFP-
YT521-B or Flag-tagged YT521-B protein. However, these
structures may reflect unphysiological protein deposits
caused by overexpressed and misfolded proteins or, alter-
natively, they may enlarge pre-existing compartments of
the endogenous protein. To clarify this situation, we inves-
tigated the localization and biochemical characteristics of
endogenous YT521-B protein using specific antisera raised
against YT521-B peptides. Immunofluorescence experi-
ments, described in this study, revealed that the distribution
of transiently expressed EGFP-YT521-B or Flag-tagged
YT521-B protein agrees with the endogenous protein,
which is concentrated in discrete compartments or dots in
a proportion of cells in different cell lines. However, it ap-
peared that the endogenous structures are usually smaller
in size and not as clearly defined as the structures seen
with EGFP-YT521-B. Endogenous YT521-B bodies more
closely resemble the pattern observed with overexpressed
Flag-tagged YT521-B constructs (Hartmann et al., 1999).
We observed a variability of YT bodies in unsynchro-
nized cells and could demonstrate that the formation of
YT bodies is regulated during the cell cycle. They ap-
peared when cells entered the S phase and persist through-
out it. This feature is shared by several dynamic subnuclear
structures (Ferreira et al., 1994; Matera, 1998), although,
in contrast, heterochromatin-associated PcG domains per-
sist during mitosis (Saurin et al., 1998). These findings sup-
port our results that YT bodies may be functionally signifi-
cant during the G1/S-phase, when transcription is active
(Wei et al., 1998). We have investigated this further and
examined transformed cells which often display changes in
their nuclear architecture, reflecting their capacity for un-
limited growth and metastatic potential (Nickerson, 1998).
Remarkably, we found that the appearance of endogenous
YT bodies was a reliable indicator of sodium butyrate,
PMA, or tamoxifen-induced differentiation of the human
cell line MCF7. MCF7 cells are a mammary adenocarci-
noma cell line and can be differentiated in vitro using
tamoxifen, sodium butyrate, or PMA. All three drugs in-
duce MCF7 differentiation, visualized by the appearance
of cytoplasmatic lipid droplets and arrest the cells in G1
(Guilbaud et al., 1990; Maas et al., 1995; Alblas et al.,
1998). Considering the cell cycle–regulated formation of
YT bodies in normal cell lines (see above), this could ex-
plain the pronounced morphology of the YT bodies in G1
arrested MCF7 cells. Moreover, since sodium butyrate is
known to induce changes in the methylation pattern of
CpG islands (Cosgrove and Cox, 1990), which is often al-
tered in breast cancer cells (Huang et al., 1999; Pilat et al.,
1998), it is interesting to note that YT bodies are most pro-
nounced in sodium butyrate–treated cells. Methylation of
CpG dinucleotides is implicated in transcriptional control
and serves as a recognition site for structural proteins
that assemble chromatin (Ashraf and Ip, 1998). However,
whether YT521-B is involved in these processes or plays a
role in the G1- to S-phase transition remains to be investi-
gated.
An increasing number of reports describe proteins that
localize to distinct subnuclear domains, and current views
suggest that the nucleus is divided into functional units
and storage compartments for nuclear proteins (sum-
marized in Lamond and Eanshaw, 1998; Spector, 1993;
Strouboulis and Wolffe, 1996; Matera, 1999). When we
compared the localization of YT521-B protein with sev-
eral other well-characterized structures, we found that
YT521-B defines a novel subnuclear compartment and
that these compartments contain focal sites of transcrip-
tion. We have termed these novel structures YT bodies.
Previously, it was shown that transcriptional activity oc-
curred in the vicinity of speckles, allowing splice factors to
be recruited into the transcriptosomal machinery (Misteli
et al., 1997). Our results demonstrate that speckles and
coiled bodies are often found in close proximity to YT
bodies, suggesting that these structures maybe functionally
linked and possibly exchange factors between them. Fur-
thermore, we suggest that YT bodies are sites of transcrip-
tional activity.
The morphology of various subnuclear structures is in-
fluenced by transcriptional activity and inhibition of tran-
scription by a-amanitin, DRB, or actinomycin D cause an
enlargement of structures, or may cause them to disperse
(Spector, 1993; Haaf and Ward, 1996; Schul et al., 1996;
Misteli et al., 1997; Huang et al., 1998; Nayler et al., 1998b;
Pombo et al., 1998). For example, the PNC changed its
structure upon DRB, a-amanitin, or actinomycin D treat-
ment (Huang et al., 1998) and the number of coiled bodies
decreased (Schul et al., 1996). Moreover, the OPT domain
is not affected by short exposures to a-amanitin, but DRB
and actinomycin D significantly reduced the number of
cells containing OPT structures (Pombo et al., 1998). Fi-The Journal of Cell Biology, Volume 150, 2000 960
nally, speckles lose connections between them, round up
and grow after inhibition of transcription with actinomycin
D, a-amanitin, or DRB (Spector et al., 1983; Misteli et al.,
1997; Nayler et al., 1998b). It is thus conceivable that stor-
age compartments generally accumulate proteins in the
absence of transcription, whereas functional units dis-
perse. We have investigated the localization of YT521-B in
the presence or absence of different transcriptional inhibi-
tors and have found a selective effect of actinomycin D on
the morphology of YT bodies. At the same time, we found
that YT521-B changes its solubility upon actinomycin D
treatment, suggesting that the YT521-B protein shuttles
between a soluble compartment, the YT bodies, and an in-
soluble compartment, where the YT521-B protein is dif-
fusely distributed. To our knowledge, these characteristics
are novel and distinguish YT bodies from previously re-
ported nuclear structures. Furthermore, the experiments
using actinomycin D, a-amanitin, or DRB suggest that the
integrity of the YT bodies does not depend directly on the
activity of RNA polymerases. Instead, our results indicate
that YT bodies form independently of transcriptional ac-
tivity, possibly through a direct or indirect DNA–protein
interaction. Indeed, in vitro nucleotide binding of YT-521-
B to polyG-agarose was observed in preliminary experi-
ments (Hartmann, A., unpublished results).
In summary, we describe a novel dynamic subnuclear
domain, the YT bodies, which contain focal sites of tran-
scription. Furthermore, our results suggest that the forma-
tion of these structures is independent of RNA poly-
merase activity and may instead depend on the integrity of
a transcriptional complex at the sites of RNA initiation.
To our knowledge, there is no other subnuclear structure
displaying similar properties, and, in analogy to models
proposed for the OPT domain (Pombo et al., 1998) and
the nucleolus, we suggest that YT521-B and its molecular
binding partners may group genes into higher-order struc-
tures. The proximity to speckles and coiled bodies would
thereby lead to the formation of efficient gene expression
centers (Fig. 8). In addition, signal transduction pathways
emanating from the Src protein kinase family might regu-
late the formation of this subnuclear domain (Hartmann
et al., 1999). Finally, future studies will clarify whether the
formation of YT bodies seen upon MCF7 cell differentia-
tion can provide a novel cancer diagnostic tool.
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